'Groundbreaking Option' Approved for Rectal Cancer

(MedPage Today) -- The FDA on Monday granted accelerated approval to the PD-1 inhibitor dostarlimab (Jemperli) to help select patients with operable rectal cancer potentially avoid surgery. The approval allows use in stage II/III patients with...